Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 22, 2011

Moleculence to Use Pronota's Platforms to Find Biomarkers for Stroke

  • Pronota signed an agreement allowing its MASStermind® platform for protein biomarker discovery and its MASSterclass™ biomarker verification platform to be used by Molecuence. The company will leverage the technologies to discover and validate protein biomarkers in stroke.

    Pronota develops protein biomarker diagnostics using a platform that mines for low-abundance protein biomarkers in blood and other tissues. MASSterclass™ verifies biomarkers identified by MASStermind® without the use of antibody-based assays, according to the company.

    Promota's pipeline consists of four programs focused on diagnostic blood tests for cardiorenal disease, pre-eclampsia, sepsis, and ovarian cancer. Founded in late 2004, Pronota announced the raising of a series B financing round of €7.9 million (about $10.8 million) last year.

    Moleculence, a wholly owned subsidiary of Mitsubishi Chemical, focuses on R&D of advanced biomarkers that can enable diagnosis and prediction of cardiovascular and metabolic diseases. Molecuence works with researchers at Kyushu University Faculty of Medicine and Hisayama Research Institute for Lifestyle Diseases.

     

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »